Healthcare Dec 10, 2021 04:48 PM (GMT+8) · EqualOcean
Today, Baiji China announced that pubeshi ® (bevacizumab injection biological similar drug) was commercially listed in China, officially began to supply drugs to major hospitals and pharmacies across the country, and issued prescriptions for patients in many hospitals across the country. At present, pubesi ® The retail price at the terminal is 3316 yuan / bottle (400mg / 16ml) and 1147 yuan / bottle (100mg / 4ml). Previously, on November 19, 2021, pubeshi ® It has been officially approved by China National Drug Administration (nmpa) for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). In 2020, there were 9.96 million cancer deaths worldwide, including 1.8 million lung cancer, far exceeding other cancer types. In China, the incidence rate of lung cancer is increasing. NSCLC accounts for about 85% of lung cancer. In China, the incidence rate of colorectal cancer has risen to third place among the most common new cancers in China. It ranks fifth among the most common causes of cancer deaths. As one of the representative drugs against tumor angiogenesis, bevacizumab has been widely used in the treatment of a variety of malignant tumors ® It is similar to the original drug in clinical efficacy, safety and immunogenicity, which will further improve accessibility. Actively promote pubesi ® At the same time of commercialization, Baiji Shenzhou has also started the self-developed anti-PD-1 antibody drug baizean ® And pubesi ® To accelerate the expansion of indication layout and benefit more patients.
Related companies: